MHC-II新抗原影响瘤免疫力和免疫治疗反应
Elise Alspach1,2, Danielle M Lussier1,2, Alexander P Miceli1,2
1Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
癌症免疫编辑和免疫治疗反应的成功取决于CD8+和CD4+T细胞. 瘤细胞必须在瘤微环境中呈现MHCII类抗原以激活CD4+T细胞以获得有效的抗瘤免疫力.
科学领域:
- 免疫学
- 癌症学
- 癌症研究
背景情况:
- 癌症免疫编辑描述了免疫系统在消除瘤中的作用.
- 针对免疫检查点的免疫疗法改善了一些癌症患者的结果.
- 患者对免疫疗法的反应有限凸显了需要更深入的理解.
研究的目的:
- 研究CD4+ T细胞在超出CD8+ T细胞的抗瘤反应中的作用.
- 确定MHCII类受限抗原的必要性,以有效排斥瘤.
- 阐明成功的癌症免疫治疗的要求.
主要方法:
- 对自发和免疫治疗诱导的抗瘤反应的分析.
- 研究T细胞子集 (CD8+和CD4+) 的参与.
- 瘤细胞主要基因相容性复合体 (MHC) II 类表达和抗原呈现的评估.
主要成果:
- CD8+和CD4+T细胞对于抗瘤免疫至关重要,即使在缺乏MHCII类表达的瘤中也是如此.
- 瘤细胞必须在瘤部位表达MHCII类受限抗原以进行排斥.
- 在瘤微环境中的CD4+T细胞激活对于有效的抗瘤反应至关重要.
结论:
- 在抗瘤免疫中,CD4+ T细胞与CD8+ T细胞发挥着至关重要的,不重叠的作用.
- 对抗瘤反应和免疫疗法的有效性至关重要.
- 确定可能受益于免疫治疗的患者需要考虑MHC类I和MHC类II新抗原.
更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
The Tumor Microenvironment
